Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization
| Autor: | Kyung Chul Yoon, Je Moon Woo, Yong Sok Ji, Hyeon Jeong Yoon |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
CD31
medicine.medical_specialty Medicine (General) Bevacizumab genetic structures Pyridines corneal neovascularization rivoceranib bevacizumab Administration Topical medicine.medical_treatment Statistics Nonparametric Article Mice 03 medical and health sciences 0302 clinical medicine R5-920 Ophthalmology Lymphatic vessel Animals Medicine Saline business.industry General Medicine medicine.disease Hyaluronan-mediated motility receptor eye diseases Mice Inbred C57BL Disease Models Animal Lymphatic system medicine.anatomical_structure 030220 oncology & carcinogenesis Corneal neovascularization 030221 ophthalmology & optometry sense organs Ophthalmic Solutions Complication business medicine.drug |
| Zdroj: | Medicina; Volume 55; Issue 11; Pages: 729 Medicina Volume 55 Issue 11 Medicina, Vol 55, Iss 11, p 729 (2019) |
| ISSN: | 1648-9144 |
| DOI: | 10.3390/medicina55110729 |
| Popis: | Background and Objectives: Corneal neovasculariziation (CNV) is a serious vision-threatening complication however, all therapeutics have their clinical limitations. The aim of this study is to investigate the efficacy of topical rivoceranib compared with topical bevacizumab in a murine model of corneal neovascularization (CNV). Materials and Methods: Murine CNV was induced by means of total de-epithelization and alkali burn. Mice were divided into five groups according to topical treatment: untreated control, phosphate-buffered saline (PBS), 0.1% and 0.5% rivoceranib, and 0.5% bevacizumab. CNV area and index were measured 7 and 14 days after treatment. After corneal tissues were excised at day 14, the blood and lymphatic vessels were quantified by cluster of differentiation 31 (CD31) and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) immunofluorescence, respectively. Results: After 14 days, treatment groups with 0.1% and 0.5% rivoceranib and 0.5% bevacizumab showed a decrease in CNV area and index compared with the untreated and PBS groups (all p < 0.01). Blood and lymphatic vascularization significantly decreased in the 0.5% rivoceranib and 0.5% bevacizumab groups, as measured by CD31 and LYVE1 immunofluorescence. There was no significant difference of vascularization between the 0.5% rivoceranib and bevacizumab groups. Conclusions: Topical application of rivoceranib could effectively decrease CNV equivalent to topical bevacizumab in a murine model. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|